RhumbLine Advisers’s Ironwood Pharmaceuticals IRWD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$677K Sell
192,934
-6,974
-3% -$28.6K ﹤0.01% 2420
2025
Q4
$674K Sell
199,908
-23,321
-10% -$60.6K ﹤0.01% 2473
2025
Q3
$292K Buy
223,229
+7,611
+4% +$7.88K ﹤0.01% 3013
2025
Q2
$155K Buy
215,618
+7,575
+4% +$5.95K ﹤0.01% 3363
2025
Q1
$306K Sell
208,043
-139,963
-40% -$333K ﹤0.01% 2879
2024
Q4
$1.54M Buy
348,006
+10,041
+3% +$40.7K ﹤0.01% 2023
2024
Q3
$1.39M Sell
337,965
-27,736
-8% -$149K ﹤0.01% 2092
2024
Q2
$2.38M Buy
365,701
+2,577
+0.7% +$18.2K ﹤0.01% 1792
2024
Q1
$3.16M Sell
363,124
-95,619
-21% -$1.16M ﹤0.01% 1668
2023
Q4
$5.25M Buy
458,743
+507
+0.1% +$5.01K 0.01% 1380
2023
Q3
$4.41M Buy
458,236
+3,935
+0.9% +$38.6K 0.01% 1433
2023
Q2
$4.83M Buy
454,301
+38,476
+9% +$414K 0.01% 1396
2023
Q1
$4.37M Buy
415,825
+15,766
+4% +$177K 0.01% 1405
2022
Q4
$4.96M Buy
400,059
+10,219
+3% +$116K 0.01% 1282
2022
Q3
$4.04M Buy
389,840
+78,396
+25% +$889K 0.01% 1356
2022
Q2
$3.59M Buy
311,444
+146,836
+89% +$1.73M 0.01% 1445
2022
Q1
$2.07M Buy
164,608
+6,277
+4% +$72K ﹤0.01% 1797
2021
Q4
$1.85M Sell
158,331
-31,531
-17% -$387K ﹤0.01% 1930
2021
Q3
$2.48M Buy
189,862
+6,173
+3% +$79.8K ﹤0.01% 1777
2021
Q2
$2.36M Sell
183,689
-8,298
-4% -$95K ﹤0.01% 1873
2021
Q1
$2.15M Sell
191,987
-10,418
-5% -$110K ﹤0.01% 1876
2020
Q4
$2.31M Sell
202,405
-14,280
-7% -$156K ﹤0.01% 1783
2020
Q3
$1.95M Sell
216,685
-63,085
-23% -$627K ﹤0.01% 1693
2020
Q2
$2.89M Buy
279,770
+40,591
+17% +$415K ﹤0.01% 1516
2020
Q1
$2.41M Buy
239,179
+19,417
+9% +$228K 0.01% 1449
2019
Q4
$2.92M Buy
219,762
+5,195
+2% +$57.3K ﹤0.01% 1576
2019
Q3
$1.84M Buy
214,567
+9,615
+5% +$93.4K ﹤0.01% 1785
2019
Q2
$2.24M Sell
204,952
-15,448
-7% -$173K ﹤0.01% 1673
2019
Q1
$2.5M Sell
220,400
-2,043
-0.9% -$22.8K ﹤0.01% 1581
2018
Q4
$1.93M Buy
222,443
+73,244
+49% +$841K ﹤0.01% 1664
2018
Q3
$2.31M Sell
149,199
-10,668
-7% -$169K ﹤0.01% 1578
2018
Q2
$2.56M Buy
159,867
+7,445
+5% +$110K 0.01% 1534
2018
Q1
$1.97M Sell
152,422
-3,368
-2% -$42K ﹤0.01% 1615
2017
Q4
$1.96M Sell
155,790
-30,086
-16% -$393K ﹤0.01% 1635
2017
Q3
$2.46M Buy
185,876
+1,793
+1% +$24.7K 0.01% 1482
2017
Q2
$2.91M Buy
184,083
+4,433
+2% +$64.4K 0.01% 1338
2017
Q1
$2.57M Buy
179,650
+7,923
+5% +$108K 0.01% 1404
2016
Q4
$2.2M Buy
171,727
+8,622
+5% +$109K 0.01% 1387
2016
Q3
$2.17M Buy
163,105
+3,388
+2% +$39.6K 0.01% 1349
2016
Q2
$1.75M Buy
159,717
+9,369
+6% +$91.5K 0.01% 1436
2016
Q1
$1.38M Buy
150,348
+2,632
+2% +$21.7K ﹤0.01% 1610
2015
Q4
$1.43M Buy
147,716
+15,331
+12% +$148K ﹤0.01% 1569
2015
Q3
$1.16M Buy
132,385
+3,017
+2% +$28.2K ﹤0.01% 1682
2015
Q2
$1.31M Sell
129,368
-6,907
-5% -$80.3K ﹤0.01% 1695
2015
Q1
$1.83M Buy
136,275
+24,459
+22% +$321K 0.01% 1459
2014
Q4
$1.44M Sell
111,816
-4,649
-4% -$53.2K ﹤0.01% 1568
2014
Q3
$1.26M Sell
116,465
-520
-0.4% -$5.95K ﹤0.01% 1604
2014
Q2
$1.5M Buy
116,985
+19,879
+20% +$216K ﹤0.01% 1563
2014
Q1
$1M Sell
97,106
-119
-0.1% -$1.34K ﹤0.01% 1799
2013
Q4
$945K Sell
97,225
-597
-0.6% -$5.36K ﹤0.01% 1852
2013
Q3
$971K Sell
97,822
-859
-0.9% -$8.43K ﹤0.01% 1800
2013
Q2
$822K Buy
+98,681
New +$1.2M ﹤0.01% 1897

Other funds holding IRWD

RhumbLine Advisers's IRWD Position: Q1 2026 in Review

RhumbLine Advisers reduced its Ironwood Pharmaceuticals (IRWD) stake by 3.5% in Q1 2026, selling an estimated $28.6K and leaving 192,934 shares worth $677K. The position accounts for ﹤0.01% of the portfolio, ranked #2420.

RhumbLine Advisers first reported a position in IRWD in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.25M in Q4 2023. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • RhumbLine Advisers held 192,934 shares of Ironwood Pharmaceuticals worth $677K as of Q1 2026.
  • RhumbLine Advisers sold 6,974 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $28.6K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2420 holding.
  • RhumbLine Advisers first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • RhumbLine Advisers's Ironwood Pharmaceuticals position peaked at $5.25M in Q4 2023.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.